Health-care companies fell sharply after reports that Donald Trump will pick Robert F. Kennedy Jr. as his nominee for head of Health and Human Services Department.

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.